JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinkas, L.
Right arrow Articles by Horne, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinkas, L.
Right arrow Articles by Horne, T.
Journal of Nuclear Medicine Vol. 42 No. 1 33-37
© 2001 by Society of Nuclear Medicine


CLINICAL INVESTIGATIONS

99mTc-MIBI Scintigraphy in Musculoskeletal Tumors

Lena Pinkas, Dror Robinson, Nahum Halperin, Lilia Mindlin, Mehrzad Cohenpour, Michal Baumer and Tifha Horne

Departments of Nuclear Medicine and Orthopedics, Assaf Harofeh Medical Center, Zerifin; and Department of Statistics, Hebrew University of Jerusalem, Jerusalem, Israel

The aim of this study was to assess the value of 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) scintigraphy in patients with clinical and radiologic features of primary or metastatic musculoskeletal tumors. Methods: The scintigraphic findings for 84 patients were compared with the surgical and histologic findings. Each patient underwent three-phase bone scanning with 99mTc-methylene diphosphonate (MDP) and dynamic and static MIBI scintigraphy. The MIBI scans were evaluated by visual and quantitative analysis. The count ratio of the lesion to the adjacent or contralateral normal area (L/N) was calculated from the region of interest drawn on the MIBI scan. The Mann–Whitney test was used to determine the differences between the uptake ratios of malignant and benign lesions. Results: Although increased MDP uptake was not specific for bone malignancy, a significant difference was found between benign tumors (L/N = 1.22 ± 0.43) and malignant tumors (L/N = 2.25 ± 1.03) on MIBI scans. Sensitivity and specificity were 81% and 87%, respectively. Forty-six of 53 proven benign lesions did not show significant MIBI uptake. The negative predictive value was 88%. In all seven sites of pathologic fracture, significant uptake was seen. However, three malignant lesions were not detected by MIBI scintigraphy, whereas seven benign lesions showed false-positive results. Conclusion: The major diagnostic worth of MIBI scintigraphy is its high negative predictive value. Although not capable of replacing tissue biopsy as a definitive diagnostic modality for musculoskeletal neoplasms, MIBI scintigraphy does appear to have a role in better preoperative assessment and in distinguishing between pathologic and simple fractures.

Key Words: musculoskeletal tumors • bone metastasis • 99mTc-MIBI scintigraphy • pathologic fractures




This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
A. Hadi, P. Hickling, M. Brown, and A. Al-Nahhas
Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis
Rheumatology, January 1, 2002; 41(1): 114 - 116.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.